Reviewer's report

Title: Safety and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor YN968D1 in Patients with Advanced Malignancies

Version: 1 Date: 26 May 2010

Reviewer: Mark McKeage

Reviewer's report:

This is a well written and presented report of an oncology phase I trial that met its objective. The following are suggestions for improvements.

*Major Compulsory Revisions
None

*Minor Essential Revisions
Pg 11 3rd line define abbreviation "HFS"
Pg 11 7th line include dose, method of administration and citation for use of glutathione

*Discretionary Revisions
pg 10 1st paragraph and table 2. Suggest adding graph of dose versus Cmax and AUC to demonstrate non-proportional PK, interindividual variability of PK and PK data for doses other than 750mg.
pg 12 paragraphs 1 and 2. What prior treatment had the responding patients received.
pg 14 and 15. The claims for greater antitumor activity of study drug compared to others in the class should be more balanced. Qualifications should be added such as these apparent differences possibly being due to patient selection and requiring further prospective comparative study.
pg 15 Conclusion. The statement above exploring a twice daily schedule should be removed as it poorly justified as it currently reads. If a specific target concentration is sought, or the drug accumulation that will occur with twice daily is considered not to be a potential problem, then this should be expanded upon.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:

I declare that I have no competing interest